Lotus

Taipei, Taiwan Founded: 1966 • Age: 60 yrs Listed Acquired By Innobic Asia
Contract manufacturing for oral solid formulations is offered.

About Lotus

Lotus is a publicly listed company based in Taipei (Taiwan) founded in 1966, and was acquired by Innobic Asia in November 2021. Contract manufacturing for oral solid formulations is offered. It operates on a Direct-to-Consumer (D2C) and Reseller / Distribution model. The company has 31 employees. Lotus has completed 1 acquisition, including Alvogen. Its chief executive, as recorded, is Robert Wessman. Its website lotuspharm.com draws about 15 thousand monthly visits. Its Indian entity Alvogen Pharma (India) Private Limited reported revenue of ₹51.32 Cr. Lotus offers products and services including Oncology Products and Generic Pharmaceuticals. Its focus areas include Pharmaceuticals and Oncology and Generics.

Company details

Lotus is established as an international pharmaceutical entity with a focus on commercializing novel and generic drugs. Headquartered in Taiwan, the company is supported by a robust RD and manufacturing platform across Asia. A diverse portfolio of high-quality, affordable medicines is delivered to markets worldwide. Operations span oncology, generics, and contract research, with over 250 products in the market and more than 100 projects in development. Strategic partnerships and in-house capabilities are leveraged to maintain competitive speed and flexibility in the industry.

  • Headquarters Taipei, Taiwan
  • Employees 31
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website lotuspharm.com
  • Social LinkedIn
  • Acquired by Innobic Asia (Nov 2021)
  • Legal Name Lotus Pharmaceutical Co., Ltd.
Key Metrics
  • Indian entity revenue
    ₹51.32 Cr

    FY 2025 · -6% YoY

  • Indian entity net profit
    ₹7.79 Cr

    FY 2025 · 15% margin

  • Indian entity EBITDA
    ₹11.25 Cr

    FY 2025 · 22% margin

  • Investors
    Alvogen

    & 2 more

  • Employee Count
    31
  • Investments & Acquisitions
  • Acquired by
    Innobic Asia

    & 1 more

    (Nov 2021)

Products & Services of Lotus

Lotus offers a comprehensive portfolio of products and services, including Oncology Products and Generic Pharmaceuticals.

Oncology Products
Pharmaceuticals

High-quality oncology drugs are developed for global markets.

Generic Pharmaceuticals
Pharmaceuticals

Affordable generic medicines are produced for various conditions.

Funding Insights of Lotus

  • Total Rounds 2

All 2 funding rounds of Lotus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2021Post-IPO––
–
Apr 2021Post-IPO––
–
Valuation history

3 investors in total: 3 institutional.

Investors in Lotus

Lotus has secured backing from 3 investors. Prominent investors backing the company include Alvogen, Aztiq and Innobic Asia.

All
InvestorDescriptionFounded YearDomainLocation
Aztiq is engaged in investments within the pharmaceutical and biotech sectors.
2009aztiq.isReykjavík, Iceland
Pharmaceutical products are developed and marketed globally.
2009alvogen.comMontville, United States
Operates as a CDMO specializing in solid-based drug production.
2021innobicasia.comChatuchak, Thailand
Premium access

Investor details for Lotus

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Alvogen Pharma (India) Private Limited (Lotus)

Alvogen Pharma (India) Private Limited is the primary company behind Lotus. The board of Alvogen Pharma (India) Private Limited currently have 4 directors; the longest-serving is Fjalar Kristjansson, appointed in 2010. 8 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Fjalar Kristjansson
DIN 02504768
Director13 Apr 201016 yrs 7 moAlvogen Pharma (India) Private Limited
Divya Chandu Patel
DIN 03132296
Nominee Director01 May 201016 yrs 6 moAlvogen Pharma (India) Private Limited
Saral Thangam
DIN 01507119
Director20 Sep 201412 yrs 2 moAlvogen Pharma (India) Private Limited
Aditya Nagaraj Bellur
DIN 07231827
Director13 Dec 20178 yrs 11 moAlvogen Pharma (India) Private Limited

People of Lotus

51 people are tracked at Lotus (24 in leadership, 7 in board & advisors, 20 in team); the tracked headcount is 31.

NameRoleGroup
Robert Wessman
CEOLeadership
Bala Krishna
Head Portfolio ManagementLeadership
Bharath Jayaraman
Head of SEA MarketsLeadership
Petar Vazharov
CEOLeadership
Eeling Chan
CFO, TaiwanLeadership
Bjartur Shen
Strategies and Finance VPLeadership
Prashant Godse
Head of Business DevelopmentLeadership
Snaevar Vidisson
Director of Export Markets, B2BLeadership
Edin Buljubasic
VP, Legal & ComplianceLeadership
Ella Tsai
Corporate Procurement HeadLeadership
Ying-Ming Yue
VP, Operations & Supply Chain ManagementLeadership
Gautam Bakshi M.pharm
Head (senior Director) - Global IP ManagementLeadership
Cy Lim
Senior Director, Marketing Excellence APACLeadership
Fiona Lei
Head Of Human ResourcesLeadership
Catherine Lee
Distribution Regulatory Affairs Director, APACLeadership
Kaushik Gupta
Associate DirectorLeadership
Vamsi Kiran Kosaraju
VP, QualityLeadership
Lucian Marcu
Director Supply Chain ManagementLeadership
Shubhashlok Dwibedy
A.i. Head (sales And Marketing) - PhilippinesLeadership
Evelyn Leo
Senior DirectorLeadership

31 more people are available in the full profile.

Premium access

Complete people profiles for Lotus

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Lotus

Lotus is a publicly listed company on the TWSE with ticker symbol 1795 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date10 Dec 2007
  • Listed onTPE: 1795
  • Listed entityLotus Pharmaceutical Co., Ltd.
  • Exchange sectorHealth technology
  • ISINTW0001795003
  • Share price180.00 TWD (+1.12% on the day) · 2026-10-14
  • Market capitalisation47,364,155,151.00 TWD
  • Price to earnings12.7
  • EPS (diluted, trailing year)14.22 TWD
  • Dividend yield1.4%
  • Volume (last session)514,745

Financials of Lotus

Figures of Alvogen Pharma (India) Private Limited, the primary company behind Lotus, for FY 2025. Revenue was ₹51.32 Cr (-6% year on year). Net profit was ₹7.79 Cr (15% margin). EBITDA was ₹11.25 Cr (22% margin). Revenue has grown at a compounded annual rate of +54% over three years and -2% over five years.

  • ₹51.32 CrRevenue · FY 2025 · -6% YoY
  • ₹7.79 CrNet profit · 15% margin
  • ₹11.25 CrEBITDA · 22% margin
  • ₹51.2 LakhPaid-up capital
  • 31Employees (provident fund records)
  • +54%Revenue CAGR, 3 years
  • -2%Revenue CAGR, 5 years
Exchange-reported annual figures
YearRevenueNet incomeEBITDA
202520.51B TWD4.72B TWD7.44B TWD
202418.58B TWD5.07B TWD7.30B TWD
202316.96B TWD4.11B TWD6.11B TWD
202214.63B TWD3.02B TWD5.05B TWD
202112.65B TWD1.40B TWD3.05B TWD

Balance sheet, profit and loss, cash flow and ratios of Alvogen Pharma (India) Private Limited are on its company page.

Premium access

Detailed financial statements for Lotus

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Lotus

Lotus has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Alvogen.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Pharmaceutical products are developed and marketed globally.
alvogen.comMontville, United States2009Sep 2025$658M
Premium access

Complete acquisition details for Lotus

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Lotus

7 dated milestones of Lotus across 59 years, from founding to its latest funding, stage changes and deals.

  1. Founded Lotus is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Exit Acquired by Alvogen.
  4. Funding First funding round.
  5. Funding Latest funding round, Post-IPO,.
  6. Exit Acquired by Innobic Asia.
  7. Acquisition Acquires Alvogen.

Web traffic of Lotus

The website of Lotus (lotuspharm.com) receives about 14.7K visits a month.

  • Monthly visits
    14.7K

    ▼ 2.3% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Lotus

Premium access

Complete news archive for Lotus

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Lotus

Lotus was founded in 1966 and raised its 1st funding round 55 years after it was founded.

Lotus is headquartered in Taipei, Taiwan.

Robert Wessman is the CEO of Lotus, as recorded in our data.

Lotus has 31 employees.

The primary company behind Lotus, Alvogen Pharma (India) Private Limited, reported revenue of ₹51.32 Cr for FY 2025, down 6% year on year.

Lotus is established as an international pharmaceutical entity with a focus on commercializing novel and generic drugs. Headquartered in Taiwan, the company is supported by a robust RD and manufacturing platform across Asia. A diverse portfolio of high-quality, affordable medicines is delivered to markets worldwide. Operations span oncology, generics, and contract research, with over 250 products in the market and more than 100 projects in development. Strategic partnerships and in-house capabilities are leveraged to maintain competitive speed and flexibility in the industry.

Lotus offers Oncology Products and Generic Pharmaceuticals.

Yes, Lotus is publicly traded on TWSE under the ticker symbol 1795.

Lotus has made 1 acquisition, including Alvogen.

Lotus has 3 investors. Key investors include Alvogen, Aztiq, and Innobic Asia.

Lotus operates through Alvogen Pharma (India) Private Limited.

Yes. Lotus was acquired by Innobic Asia in November 2021.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available